Patents by Inventor James G. Karras
James G. Karras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8765700Abstract: A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin ?4 comprising administering to the animal a composition comprising from. 0.001 to 1000 ?g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin ?4.Type: GrantFiled: October 20, 2005Date of Patent: July 1, 2014Assignee: Antisense Therapeutics Ltd.Inventors: George Tachas, James G. Karras, Susan Gregory, Jeffrey R. Crosby, Kenneth W. Dobie, Frank C. Bennett
-
Patent number: 8722873Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.Type: GrantFiled: February 22, 2010Date of Patent: May 13, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, James G. Karras
-
Patent number: 8623643Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: GrantFiled: April 19, 2012Date of Patent: January 7, 2014Assignee: Isis Pharmaceuticals, Inc.Inventor: James G. Karras
-
Patent number: 8476421Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.Type: GrantFiled: February 22, 2010Date of Patent: July 2, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, James G. Karras
-
Publication number: 20120316221Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.Type: ApplicationFiled: February 29, 2012Publication date: December 13, 2012Applicant: ISIS PHARMACEUTICALS, INC.Inventors: JAMES G. KARRAS, SUSAN GREGORY, JEFFREY R. CROSBY, MAUSUMEE GUHA, DAVID TUNG, SUSAN M. FREIER, KENNETH W. DOBIE
-
Publication number: 20120309815Abstract: The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.Type: ApplicationFiled: April 4, 2012Publication date: December 6, 2012Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sujatha Dokka, Scott Cooper, Susan Kelly, Greg Hardee, James G. Karras
-
Publication number: 20120202874Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: ApplicationFiled: April 19, 2012Publication date: August 9, 2012Applicant: Isis Pharmaceuticals, Inc.Inventor: James G. Karras
-
Patent number: 8183363Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: GrantFiled: April 23, 2009Date of Patent: May 22, 2012Assignee: Isis Pharmaceuticals, Inc.Inventor: James G. Karras
-
Patent number: 8168600Abstract: The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.Type: GrantFiled: April 21, 2005Date of Patent: May 1, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Sujatha Dokka, Scott Cooper, Susan Kelly, Gregory E. Hardee, James G. Karras
-
Patent number: 8153603Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.Type: GrantFiled: February 24, 2006Date of Patent: April 10, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: James G. Karras, Susan Gregory, Jeffrey R. Crosby, Mausumee Guha, David Tung, Susan M. Freier
-
Patent number: 7981868Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.Type: GrantFiled: August 12, 2004Date of Patent: July 19, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Kenneth W. Dobie, Susan M. Freier, Ian Popoff, James G. Karras
-
Publication number: 20110054003Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.Type: ApplicationFiled: April 23, 2009Publication date: March 3, 2011Applicant: Isis Pharmaceuticals, Inc.Inventor: James G. Karras
-
Publication number: 20100222231Abstract: A method for identifying one or more genes involved in a phenotype of cells, tissues or organisms, comprising the steps of contacting cells, tissues or organisms which exhibit the phenotype with a library of antisense oligonucleotides and performing a primary phenotypic assay to determine which antisense oligonucleotides in the library attenuate the phenotype. These antisense oligonucleotides correspond to genes involved in the phenotype. The method may be used to identify genes involved in various disease states.Type: ApplicationFiled: March 3, 2010Publication date: September 2, 2010Applicant: Isis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Alexander H. Borchers, James G. Karras
-
Patent number: 7709628Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.Type: GrantFiled: November 3, 2006Date of Patent: May 4, 2010Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, James G. Karras
-
Publication number: 20100056606Abstract: Provided herein is a method for reducing the amount of steroid required for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness, comprising administration of the steroid and an oligonucleotide targeted to IL-4R alpha. Also described is a method for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness comprising administration of a corticosteroid and an oligonucleotide targeted to IL-4R alpha. Further provided are compositions comprising a corticosteroid and an IL-4R alpha targeted antisense oligonucleotide.Type: ApplicationFiled: October 3, 2006Publication date: March 4, 2010Applicant: ISIS Pharmaceuticals, Inc.Inventors: James G. Karras, Susan Gregory
-
Publication number: 20090312398Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.Type: ApplicationFiled: February 24, 2006Publication date: December 17, 2009Applicant: ISIS PHARMACEUTICALS, INC.Inventors: James G. Karras, Susan Gregory, Jeffrey R. Crosby, Mausumee Guha, David Tung, Susan M. Freier
-
Publication number: 20090281169Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.Type: ApplicationFiled: April 16, 2009Publication date: November 12, 2009Applicant: ISIS PHARMACEUTICALS, INC.Inventors: James G. Karras, Susan Gregory, Susan M. Freier, Kenneth W. Dobie
-
Patent number: 7585968Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and/or pulmonary inflammation.Type: GrantFiled: March 27, 2006Date of Patent: September 8, 2009Assignee: Isis Pharmaceuticals, Inc.Inventors: James G. Karras, Kenneth W. Dobie
-
Patent number: 7507810Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.Type: GrantFiled: October 11, 2006Date of Patent: March 24, 2009Assignee: ISIS Pharmaceuticals, Inc.Inventors: James G. Karras, Susan Gregory, Susan M. Freier, William A. Gaarde, Mausumee Guha
-
Publication number: 20090023599Abstract: A method for identifying one or more genes involved in a phenotype of cells, tissues or organisms, comprising the steps of contacting cells, tissues or organisms which exhibit the phenotype with a library of antisense oligonucleotides and performing a primary phenotypic assay to determine which antisense oligonucleotides in the library attenuate the phenotype. These antisense oligonucleotides correspond to genes involved in the phenotype. The method may be used to identify genes involved in various disease states.Type: ApplicationFiled: July 24, 2008Publication date: January 22, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Alexander H. Borchers, James G. Karras